Medtronic plc.
MDT
Positions held
Your positionsMDT isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Medtronic is well-positioned in the medical devices industry, leveraging its strong market presence and innovative product pipeline to maintain competitive advantage.
- In the most recent quarter, Medtronic reported a revenue of $9.8 billion, consistent with the prior quarter, indicating stability in sales.
- The company's operating margin improved to 20.5% in Q2 2026, up from 18.8% in Q3 2026, showcasing operational efficiency.
- The medical devices sector faces regulatory challenges that could impact Medtronic's ability to bring new products to market quickly.
- Medtronic's net income decreased to $1.24 billion in Q2 2026 from $1.47 billion in Q3 2026, reflecting potential profitability concerns.
- The company's gross margin slightly declined to 65% in the latest quarter, down from 65.4% in the previous quarter, indicating pressure on margins.
Fundamentals
| Market cap | $112.24B | Enterprise value | $132.20B | Trailing P/E | 21.56 | Forward P/E | 13.68 |
| PEG | 1.54 | Price / book | 2.24 | Beta | 0.57 | Dividend yield | 3.28% |
| Revenue growth | 13.7% | Earnings growth | 40.7% | Gross margin | 65.3% | Operating margin | 19.3% |
| Profit margin | 13.9% | ROE | 10.6% | ROA | 5.1% | Debt / equity | 0.55 |
| Current ratio | 2.07 | Free cash flow | $5.41B | Analyst recommendation | buy | Mean target | $104.44 |
| 52w high | $106.33 | 52w low | $73.31 |
Quarterly
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|---|
| Revenue | $9.8B | $9.8B | $9.0B | $9.0B | $8.6B | — |
| Op margin | 18.8% | 20.5% | 17.8% | 18.9% | 17.7% | — |
| Net income | $1.5B | $1.2B | $1.1B | $1.4B | $1.0B | — |
| Gross margin | 65.0% | 65.4% | 63.8% | 65.8% | 65.0% | — |
| Gross profit | $6.3B | $6.4B | $5.8B | $5.9B | $5.6B | — |
| Operating income | $1.8B | $2.0B | $1.6B | $1.7B | $1.5B | — |
- Revenue -1% vs prior quarter ($9.8B vs $9.8B).
- Gross margin 65% (was 65.4% prior quarter).
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Revenue | $36.4B | $33.5B | $32.4B | $31.2B |
| Op margin | 18.8% | 19.5% | 17.1% | 18.7% |
| Net income | $4.8B | $4.7B | $3.7B | $3.8B |
| Gross margin | 65.0% | 65.3% | 65.3% | 65.7% |
| Gross profit | $23.6B | $21.9B | $21.1B | $20.5B |
| Operating income | $6.8B | $6.5B | $5.5B | $5.8B |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · How Investors Are Reacting To Medtronic (MDT) Advancing Altaviva, Symplicity Spyral And Spinning Off MiniMed
2026-10-09 · Medtronic (MDT) Commits $700 Million To Robotics As 2026 Impact Report Lands
2026-10-08 · Is Medtronic (MDT) On Its Way to Become a Multi-Platform Powerhouse?
2026-10-08 · Medtronic Is Just 1 Year From Dividend King Status. Should You Buy the Stock Before It Gets There?
2026-10-08 · The Monopolistic Razor-and-Blade Engine I Can’t Stop Buying
2026-10-07 · Medtronic Announces Final Exchange Ratio of 4.5939 in Split-Off of MiniMed Group, Inc.
2026-10-07 · Medtronic names Felicia Kurz as cardiac ablation VP, GM
2026-10-07 · Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
2026-10-07 · The "Trumpflation" Trade Could Get Worse Before It Gets Better. History Says These 2 Stocks Are the Place to Hide.
2026-10-06 · Better Dividend Play for Retirees: MDT or ABT? One Delivers Significantly More Yield
2026-10-06 · Medtronic Impact Report Highlights More Than 82 Million Patients Served Worldwide in Fiscal Year 2026
2026-10-06 · Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown?
Price (daily)
Full chart · RSI · MACD · patterns